BEAM - Beam Therapeutics Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 2.62B
Enterprise value 1.74B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)31.77
Price/book (mrq)3.44
Enterprise value/revenue 22.63
Enterprise value/EBITDA -5.02

Trading information

Stock price history

Beta (5Y monthly) 1.63
52-week change 3-9.09%
S&P500 52-week change 36.21%
52-week high 373.27
52-week low 328.04
50-day moving average 332.18
200-day moving average 341.57

Share statistics

Avg vol (3-month) 3928.39k
Avg vol (10-day) 3621.99k
Shares outstanding 576.22M
Implied shares outstanding 6N/A
Float 862.72M
% held by insiders 11.90%
% held by institutions 185.44%
Shares short (14 May 2023) 413.15M
Short ratio (14 May 2023) 415.29
Short % of float (14 May 2023) 422.30%
Short % of shares outstanding (14 May 2023) 417.26%
Shares short (prior month 13 Apr 2023) 412.87M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)-470.93%

Management effectiveness

Return on assets (ttm)-16.21%
Return on equity (ttm)-36.14%

Income statement

Revenue (ttm)76.7M
Revenue per share (ttm)1.08
Quarterly revenue growth (yoy)187.10%
Gross profit (ttm)-250.67M
EBITDA -345.7M
Net income avi to common (ttm)-287.42M
Diluted EPS (ttm)-4.70
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.06B
Total cash per share (mrq)14.32
Total debt (mrq)178.86M
Total debt/equity (mrq)23.49
Current ratio (mrq)4.93
Book value per share (mrq)10.55

Cash flow statement

Operating cash flow (ttm)-305.78M
Levered free cash flow (ttm)-174.19M